HCA's headline operating performance is solid, with revenue of $19.8B in 2026Q3 and diluted EPS of $7.27, yet growth has moderated from 10.3% in Q2 2024 to 3.6% in Q3 2026, suggesting the volume recovery is losing momentum.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has slowed toward mid-single digits, with 2026Q3 revenue of $19.8B up only 3.6% and net margin of 8.0% versus 8.8% a year earlier, suggesting modest margin pressure.
HCA Healthcare has demonstrated strong margin expansion, contributing to significant stock price appreciation.
The company is leveraging AI to drive productivity and operational efficiency, further boosting margins.
Growth in ambulatory care services is a key driver of value creation for HCA.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 27, 2026 | $7.22+8.6% vs $6.65 | $19.8B+2.7% vs $19.3B |
Q3 2026 Jul 24, 2026 | $7.59+0.4% vs $7.56 | $20.2B+2.4% vs $19.8B |
Q2 2026 Apr 24, 2026 | $7.15+0.4% vs $7.12 | $19.1B+0.1% vs $19.1B |
Q1 2026 Jan 27, 2026 | $8.01+7.4% vs $7.46 | $19.5B-0.9% vs $19.7B |
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
HCA posted its biggest one-day jump in four years before a single law changed. Wall Street is pricing in relief that needs Congress, a presidential signature, and a December funding fight to survive.
HCA Healthcare (HCA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, HCA broke through the 20-day moving average, which suggests a short-term bullish trend.
The stocks of big operators in state Medicaid programs, Affordable Care Act markets and hospital groups all jumped.
Benchmark HCA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for HCA Healthcare, Inc. (HCA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $494.99 | $107.17B | 15.87 | 7.08% | 8.61% | — | 0.59% | |
| $283.33 | $24.41B | 7.88 | 3.12% | 12.71% | 32.11% | — | |
| $2.21 | $311.63M | -0.58 | -1.18% | -2.34% | — | — | |
| $195.50 | $11.83B | 7.91 | 9.71% | 7.96% | 19.27% | 0.41% | |
| $181.08 | $10.55B | 26.91 | 18.72% | 7.03% | 16.61% | 0.14% | |
| $37.00 | $3.44B | -3.01 | 5.04% | -33.07% | -51.55% | — |
HCA Healthcare, Inc. (HCA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
HCA Healthcare, Inc. (HCA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 2, 2026·SEC
Oct 27, 2026·SEC
Jul 29, 2026·SEC
Get notified when HCA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HCA Healthcare, Inc. (HCA) stock FAQ — growth, dividends, profitability & financials explained
HCA Healthcare, Inc. (HCA) reported $78.70B in revenue over the trailing twelve months. Revenue was $75.60B in fiscal year 2025. That is 280% more than the $19.91B of fiscal year 1996.
HCA Healthcare, Inc. (HCA) grew revenue by 5.8% over the trailing twelve months, compared with the twelve months before.
Yes. HCA Healthcare, Inc. (HCA) earned $6.78B in net income over the trailing twelve months (a 8.6% net margin).
Yes. HCA Healthcare, Inc. (HCA) pays a dividend that yields 0.59% at the current price, a small yield.
HCA Healthcare, Inc. (HCA) generated $5.97B in free cash flow over the trailing twelve months.
